Vemurafenib (PLX4032)
别名: RG7204, RO5185426,PLX4032
中文名称:维罗非尼
目录号:S1267 Purity: 99.98%
Vemurafenib (PLX4032, RG7204, RO5185426)是一种新型有效的B-RafV600E抑制剂,IC50为31 nM。Vemurafenib对B-RafV600E的选择性比对野生型B-Raf的选择性高10倍,在细胞实验中,选择性可高100倍以上。Vemurafenib (PLX4032, RG7204) 可诱导自噬。
CAS: 918504-65-1
客户使用Selleck的Vemurafenib (PLX4032)发表文献664篇
- Cell, 2024 187(14):3652-3670.e40
- Nat Biotechnol, 2024 10.1038/s41587-024-02512-9
- Nature, 2023 620(7974):651-659
- Nat Cancer, 2023 4(2):240-256
- Cell, 2022 185(11):1974-1985.e12
- Blood, 2022 blood.2021014304
- Cancer Cell, 2021 S1535-6108(21)00659-0
- Nat Biotechnol, 2021 10.1038/s41587-021-00837-3
- Nat Genet, 2021 53(1):76-85
- Cell Metab, 2021 S1550-4131(21)00180-7
- Cancer Discov, 2021 candisc.0508.2021
- Nat Cell Biol, 2021 23(9):978-991
- Cell, 2020 182(4):947-959.e17
- Cancer Cell, 2020 37(1):85-103
- Cancer Cell, 2020 38(6):872-890.e6
- Nat Biotechnol, 2020 10.1038/s41587-020-0600-6
- Nat Biotechnol, 2020 10.1038/s41587-019-0388-4
- Cancer Cell, 2019 36(1):68-83
- Cancer Discov, 2019 9(7):852-871
- Nat Cell Biol, 2019 10.1038/s41556-019-0415-1
- Nat Cell Biol, 2019 21(6):778-790
- Cell, 2018 173(6):1413-1425
- Science, 2018 361(6405)
- Cancer Cell, 2018 33(2):322-336
- Cancer Cell, 2018 33(5):890-904.e5
- Cancer Cell, 2018 9;34(1):56-68.e9
- Mol Cancer, 2018 17(1):145
- Cell Metab, 2018 28(6):817-832
- Nat Biomed Eng, 2018 2(8):578-588
- Nature, 2017 547(7664):453-457
- Nature, 2017 550(7674):133-136
- Nature, 2017 546(7658):431-435
- Nat Med, 2016 22(9):1056-61
- Nat Med, 2016 22(6):624-31
- Nature, 2016 538(7626):477-482
- Nature, 2016 10.1038/nature19347
- Science, 2016 352(6282):189-96
- Cancer Cell, 2016 12;30(3):485-498
- Nat Biotechnol, 2016 34(2):184-191
- Cell Stem Cell, 2016 19(6):738-751
- Nature, 2015 10.1038/nature14336
- Mol Cancer, 2015 14:128
- Cancer Discov, 2015 10.1158/2159-8290.CD-15-0913
- Cancer Discov, 2015 5(3):264-73
- Cancer Discov, 2015 5(4):358-67
- Nat Cell Biol, 2015 17(3):322-332
- Nature, 2014 508(7494):118-22
- Science, 2014 346(6205):1255784
- Mol Cancer, 2014 13:194
- Cancer Discov, 2014 4(1):69-79
- Blood, 2014 123(20):3152-5
- Cancer Discov, 2013 3(3):350-62
- Nat Med, 2012 18(8):1239-47
- Nature, 2012 483(7387):100-3
- Cell, 2012 21;151(5):937-50.
- Cancer Discov, 2012 2(5):414-24
- Nat Commun, 2024 15(1):4108
- Nat Commun, 2024 15(1):2163
- J Clin Invest, 2024 134(6)e171063
- MedComm (2020), 2024 5(8):e684
- Cell Rep, 2024 S2211-1247(24)00376-0
- Cell Rep, 2024 43(10):114831
- Cell Rep, 2024 43(9):114710
- Oncogene, 2024 43(20):1489-1505
- Front Immunol, 2024 15:1336566
- Cell Death Discov, 2024 10(1):175
- Biochem Pharmacol, 2024 219:115952
- J Clin Endocrinol Metab, 2024 dgae589
- Int J Mol Sci, 2024 25(16)8956
- Int J Mol Sci, 2024 25(21)11853
- Mol Cancer Res, 2024 10.1158/1541-7786.MCR-24-0151
- Eur J Pharmacol, 2024 985:177058
- Transl Oncol, 2024 45:101991
- Front Oncol, 2024 14:1191217
- Biomedicines, 2024 12(3)698
- Hum Cell, 2024 10.1007/s13577-024-01034-5
- Biochem J, 2024 481(6):405-422
- BMC Pharmacol Toxicol, 2024 25(1):25
- NAR Cancer, 2024 6(2):zcae018
- Cancer Res Commun, 2024 10.1158/2767-9764.CRC-24-0221
- bioRxiv, 2024 2024.07.25.604999
- bioRxiv, 2024 2024.09.26.615226
- Nat Commun, 2023 14(1):7130
- Nat Commun, 2023 14(1):3251
- Cell Rep Med, 2023 S2666-3791(23)00367-1
- Mol Ther, 2023 10.1016/j.ymthe.2023.11.021
- Genome Biol, 2023 10.1186/s13059-023-03087-5
- EMBO Mol Med, 2023 15(3):e16629
- Sci Data, 2023 10(1):203
- Cell Death Dis, 2023 14(12):827
- Cell Death Dis, 2023 14(10):680
- Br J Cancer, 2023 10.1038/s41416-023-02282-2
- Cell Death Dis, 2023 14(7):454
- Int J Cancer, 2023 10.1002/ijc.34702
- NPJ Precis Oncol, 2023 7(1):132
- Front Immunol, 2023 14:1187388
- Cells, 2023 12(9)1317
- Cells, 2023 13(1)73
- Comput Struct Biotechnol J, 2023 21:1157-1168
- Cancer Cell Int, 2023 23(1):21
- Mol Cancer Ther, 2023 22(1):52-62
- Int J Mol Sci, 2023 24(3)1963
- Int J Mol Sci, 2023 24(4)3418
- Int J Mol Sci, 2023 24(5)4961
- Int J Mol Sci, 2023 24(13)11153
- Int J Mol Sci, 2023 24(9)8037
- Biomolecules, 2023 13(8)1212
- Oncotarget, 2023 10.18632/oncotarget.28517
- Mol Cancer Res, 2023 21(6):578-590
- Cancers (Basel), 2023 15(18)4505
- Cancers (Basel), 2023 15(3)918
- Cancers (Basel), 2023 15(3)894
- Front Oncol, 2023 13:1210130
- Biomedicines, 2023 11(7)2054
- Front Oncol, 2023 13:1182853
- Heliyon, 2023 9(7):e17714
- J Cancer, 2023 14(9):1592-1604
- Microbiol Spectr, 2023 11(4):e0055223
- Sci Adv, 2023 9(7):eadd7969
- Sci Adv, 2023 9(35):eade7486
- bioRxiv, 2023 2023.08.04.551952
- Nat Commun, 2022 13(1):6323
- Nat Commun, 2022 13(1):7113
- Nat Commun, 2022 13(1):6239
- Nat Commun, 2022 13(1):1588
- Nat Commun, 2022 13(1):4109
- Mol Cell, 2022 82(20):3919-3931.e7
- Hepatology, 2022 10.1002/hep.32574
- Cancer Res, 2022 82(24):4555-4570
- EMBO Mol Med, 2022 14(12):e15677
- EMBO Mol Med, 2022 14(3):e15295
- J Adv Res, 2022 S2090-1232(22)00254-5
- Pharmacol Res, 2022 182:106323
- Cell Death Dis, 2022 13(8):692
- Cell Death Dis, 2022 13(2):124
- Cell Rep, 2022 41(9):111728
- Cell Rep, 2022 40(5):111147
- Cell Rep, 2022 38(10):110490
- JCI Insight, 2022 7(19)e156577
- Cell Mol Life Sci, 2022 80(1):6
- JCI Insight, 2022 7(22e158060)
- Oncogene, 2022 10.1038/s41388-021-01920-4
- Oncogene, 2022 41(32):3953-3968
- EMBO Rep, 2022 23(11):e54746
- Antioxidants (Basel), 2022 11(6)1171
- Mol Oncol, 2022 10.1002/1878-0261.13217
- J Invest Dermatol, 2022 S0022-202X(22)00096-3
- J Invest Dermatol, 2022 S0022-202X(22)00391-8
- Cells, 2022 11(7)1229
- Commun Biol, 2022 5(1):101
- iScience, 2022 25-11:105282
- Mol Cancer Ther, 2022 21(6):1020-1029
- Int J Mol Sci, 2022 23(8)4277
- Int J Mol Sci, 2022 23(2415650)
- Front Pharmacol, 2022 13:906043
- Front Pharmacol, 2022 13:950571
- Biomolecules, 2022 12(7)993
- Front Cell Dev Biol, 2022 10:927118
- J Cell Mol Med, 2022 26(22):5680-5689
- Cancers (Basel), 2022 14(21)5215
- Cancers (Basel), 2022 14(19)4930
- Cancers (Basel), 2022 14(3)673
- Cancers (Basel), 2022 14(21)5449
- J Pers Med, 2022 12(2)258
- J Biol Chem, 2022 S0021-9258(22)00796-7
- Front Oncol, 2022 12:762180
- Front Oncol, 2022 12:794216
- Molecules, 2022 27(22)7800
- Sci Rep, 2022 12(1):13796
- Sci Rep, 2022 12(1):14395
- Sci Rep, 2022 12(1):16269
- Sci Rep, 2022 12(1):1626
- Sci Rep, 2022 12(1):5076
- Life Sci Alliance, 2022 5(10)e202201445
- Life Sci Alliance, 2022 5(9)e202101235
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Dis Model Mech, 2022 15(5)dmm049401
- Exp Dermatol, 2022 10.1111/exd.14677
- FEBS Lett, 2022 10.1002/1873-3468.14376
- Drug Chem Toxicol, 2022 1-10
- Anticancer Drugs, 2022 10.1097/CAD.0000000000001344
- Cancer Rep (Hoboken, 2022 e1736
- Nat Commun, 2021 12(1):1747
- Nucleic Acids Res, 2021 49(8):4421-4440
- Nat Chem Biol, 2021 10.1038/s41589-021-00947-8
- Dev Cell, 2021 S1534-5807(21)00562-1
- Clin Cancer Res, 2021 clincanres.3752.2020
- Clin Cancer Res, 2021 10.1158/1078-0432.CCR-21-2660
- Redox Biol, 2021 46:102110
- J Exp Clin Cancer Res, 2021 40(1):22
- J Exp Clin Cancer Res, 2021 40(1):34
- Cancer Res, 2021 81(11):2918-2929
- Cancer Res, 2021 81(23):6044-6057
- Cancer Res, 2021 81(20):5230-5241
- EMBO Mol Med, 2021 e11814
- EMBO Mol Med, 2021 e12924
- EMBO Mol Med, 2021 e13466
- J Control Release, 2021 S0168-3659(21)00085-7
- Cell Rep, 2021 35(8):109157
- Cell Chem Biol, 2021 S2451-9456(21)00356-1
- Oncogene, 2021 10.1038/s41388-021-01808-3
- NPJ Precis Oncol, 2021 5(1):68
- Elife, 2021 10e63093
- EMBO Rep, 2021 e51436
- Mol Oncol, 2021 15(7):1835-1848
- Genomics Inform, 2021 19(1):e2
- Int J Mol Sci, 2021 22(11)5744
- Commun Biol, 2021 4(1):1405
- J Clin Endocrinol Metab, 2021 dgab020
- Mol Cancer Ther, 2021 10.1158/1535-7163.MCT-20-1126
- Cancer Sci, 2021 112(7):2884-2894
- Int J Mol Sci, 2021 22(17)9151
- Int J Mol Sci, 2021 22(1)E439
- Int J Mol Sci, 2021 22(24)13187
- Int J Mol Sci, 2021 22(6)3226
- Cancer Biol Med, 2021 j.issn.2095-3941.2020.0560
- Front Cell Dev Biol, 2021 9:665673
- Cancers (Basel), 2021 13(3)555
- Cancers (Basel), 2021 13(4)740
- Cancers (Basel), 2021 13(15)3805
- Cancers (Basel), 2021 13(3)524
- Cancers (Basel), 2021 13(6)1205
- Cancers (Basel), 2021 13(20)5231
- Cancers (Basel), 2021 13(14)3635
- Int J Oncol, 2021 59(3)70
- Cancers (Basel), 2021 13(9)2284
- Chem Biol Interact, 2021 351:109747
- Biomedicines, 2021 9(1)E79
- Front Oncol, 2021 11:698888
- Front Oncol, 2021 11:780654
- Molecules, 2021 26(7)1867
- Sci Rep, 2021 11(1):11023
- Sci Rep, 2021 11(1):4390
- Mol Carcinog, 2021 60(3):201-212
- Sci Rep, 2021 11(1):15473
- J Proteome Res, 2021 10.1021/acs.jproteome.1c00550
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Oncol Rep, 2021 45(4)14
- Cancer Med, 2021 10(8):2840-2854
- BMC Cancer, 2021 21(1):136
- J Cancer Res Clin Oncol, 2021 10.1007/s00432-021-03545-2
- Biochem Biophys Res Commun, 2021 573:93-99
- Biochem Biophys Res Commun, 2021 557:213-220
- Cancer Chemother Pharmacol, 2021 10.1007/s00280-021-04270-w
- Oncol Lett, 2021 21(3):208
- Oncol Lett, 2021 21(5):394
- Anticancer Drugs, 2021 32(10):1076-1083
- Melanoma Res, 2021 31(3):197-207
- Sci Adv, 2021 7(24)eabg0390
- Nat Commun, 2020 11(1):4370
- Nat Commun, 2020 11;11(1):2345
- J Clin Invest, 2020 3;130(2):853-862
- Clin Cancer Res, 2020 10.1158
- J Exp Clin Cancer Res, 2020 39(1):38
- Genes Dev, 2020 1;34(9-10):637-649
- Cancer Lett, 2020 S0304-3835(20)30635-2
- Cell Rep, 2020 31(11):107764
- Br J Cancer, 2020 10.1038/s41416-020-0751-8
- Cell Commun Signal, 2020 18(1):156
- Oncogene, 2020 39(20):4132-4154
- Oncogene, 2020 10.1038/s41388-020-1255-y
- J Transl Med, 2020 11;18(1):192
- Sci Signal, 2020 28;13(629)
- Apoptosis, 2020 25(3-4):179-191
- Antioxidants (Basel), 2020 5;9(5) pii: E384
- Mol Oncol, 2020 24
- Int J Cancer, 2020 146(7):1950-1962
- Oncogenesis, 2020 9(7):64
- Cells, 2020 7;9(1). pii: E142
- Cells, 2020 13;9(5) pii: E1209
- Commun Biol, 2020 2;3(1):154
- Cancer Cell Int, 2020 19;20:58
- J Clin Endocrinol Metab, 2020 dgaa656
- Biochem Pharmacol, 2020 171:113716
- Mol Ther Oncolytics, 2020 18:83-99
- Mol Ther Oncolytics, 2020 18:100-108
- Int J Mol Sci, 2020 18;21(8):2825
- Biomolecules, 2020 10(10)E1395
- Cancers (Basel), 2020 12(8):E2085
- Aging (Albany NY), 2020 12(1):138-155
- Cancers (Basel), 2020 12(12)E3855
- Cancers (Basel), 2020 12(7):E1972
- Cancers (Basel), 2020 12(6)1500
- Cancers (Basel), 2020 12(10)E2951
- Transl Oncol, 2020 13(2):441-451
- Neoplasia, 2020 22(9):376-389
- J Biol Chem, 2020 jbc.RA120.014615
- J Biol Chem, 2020 30 pii: jbc
- Neoplasia, 2020 22(10):470-483
- Front Oncol, 2020 3;10:442
- Pharmaceuticals (Basel), 2020 14(1)E23
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Pigment Cell Melanoma Res, 2020 10.1111/pcmr.12905
- BMC Cancer, 2020 20(1):129
- PLoS One, 2020 15(6):e0234707
- PLoS One, 2020 15(1):e0227187
- Endocrine, 2020 10.1007/s12020-020-02417-y
- Cancer Manag Res, 2020 12:7231-7250
- Pathol Oncol Res, 2020 10.1007/s12253-020-00834-y
- Anticancer Drugs, 2020 31(10):1026-1037
- Sci Adv, 2020 22;6(21):eaaz8521
- J Chemother, 2020 32(8):437-444
- Transl Cancer Res, 2020 9(3):1584-1593
- Data Brief, 2020 22;30:105610
- Nat Commun, 2019 10(1):5157
- Nat Commun, 2019 10(1):5167
- Mol Cell, 2019 76(6):872-884
- Mol Cell, 2019 75(4):669-682
- Mol Cell, 2019 74(5):1086-1102.e5
- Cell Death Differ, 2019 26(7):1267-1282
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-18-2779
- Clin Cancer Res, 2019 10.1158/1078-0432
- EMBO J, 2019 38(15):e95874
- J Exp Clin Cancer Res, 2019 38(1):56
- J Exp Clin Cancer Res, 2019 38(1):48
- Cancer Res, 2019 79(19):5074-5087
- Cancer Res, 2019 79(9):2124-2135
- Cancer Res, 2019 79(9):2244-2256
- J Control Release, 2019 309:158-172
- Cancer Lett, 2019 451:79-91
- Cancer Lett, 2019 444:45-59
- Cancer Lett, 2019 451:11-22
- Cell Syst, 2019 8(2):97-108
- Cell Death Dis, 2019 10(5):342
- Mol Ther Nucleic Acids, 2019 18:727-738
- Cell Rep, 2019 27(12):3573-3586.e7
- Cell Rep, 2019 29(1):118-134
- Cell Rep, 2019 26(1):65-78
- Cell Rep, 2019 29(3):573-588
- Oncogene, 2019 38(12):2005-2019
- Apoptosis, 2019 24(7-8):596-611
- Acta Neuropathol Commun, 2019 7(1):128
- Mol Oncol, 2019 13(9):1836-1854
- Mol Oncol, 2019 13(2):480-494
- Int J Cancer, 2019 10.1002/ijc.32432
- Stem Cell Reports, 2019
- Clin Epigenetics, 2019 11(1):196
- Mol Cancer Ther, 2019 18(2):289-300
- Mol Cancer Ther, 2019 18(5):937-946
- Front Pharmacol, 2019 10:30
- Int J Mol Sci, 2019 20(17)E4203
- J Cell Physiol, 2019 234(8):13220-13232
- Int J Mol Sci, 2019 20(18)
- Int J Mol Sci, 2019 20(9)
- Oncotarget, 2019 10(18):1669-1687
- Mol Cell Biol, 2019 39(14)
- Cancers (Basel), 2019 11(10)
- Cancers (Basel), 2019 20;12(1). pii: E28
- Mol Cancer Res, 2019 10.1158/1541-7786.MCR-19-0257
- Cancers (Basel), 2019 11(9)
- Transl Oncol, 2019 12(7):951-958
- Mol Pharm, 2019 16(9):3904-3915
- Sci Rep, 2019 9(1):10369
- Sci Rep, 2019 9(1):636
- Sci Rep, 2019 9(1):9943
- Sci Rep, 2019 9(1):14197
- Mol Carcinog, 2019 58(9):1680-1690
- Mol Carcinog, 2019 58(11):2149-2160
- Sci Rep, 2019 9(1):30
- J Oncol, 2019 2019:1697913
- Invest Ophthalmol Vis Sci, 2019 60(7):2764-2772
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12824
- Pigment Cell Melanoma Res, 2019 32(1):41-54
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12812
- Pigment Cell Melanoma Res, 2019 32(2):280-291
- PLoS Comput Biol, 2019 15(6):e1007034
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12841
- Hum Cell, 2019 10.1007/s13577-019-00270-4
- Mol Cell Biochem, 2019 10.1007/s11010-019-03554-3
- Oncol Rep, 2019 41(1):570-578
- Tissue Eng Part A, 2019 10.1089/ten.TEA.2018.0210
- ACS Chem Biol, 2019 14(7):1426-1435
- ACS Chem Biol, 2019 10.1021/acschembio-00191
- J Cell Biochem, 2019 120(4):5315-5325
- Exp Gerontol, 2019 126:110691
- Endocr Relat Cancer, 2019 26(8):699-712
- Endocr Relat Cancer, 2019 26(1):197-214
- J Cancer, 2019 10(16):3819-3829
- BMC Cancer, 2019 19(1):266
- Endocrine, 2019 10.1007/s12020-019-02028-2
- PLoS One, 2019 14(4):e0204387
- PLoS One, 2019 14(6):e0217399
- Endocrine, 2019 64(2):406-413
- Exp Dermatol, 2019 10.1111/exd.14010
- Mol Pharmacol, 2019 96(1):36-46
- Chembiochem, 2019 10.1002/cbic.201900266
- Arch Dermatol Res, 2019 10.1007/s00403-019-01995-w
- Photodermatol Photoimmunol Photomed, 2019 10.1111/phpp.12520
- Nat Commun, 2018 9(1):3440
- Nat Commun, 2018 9(1):579
- Nat Commun, 2018 9(1):4775
- Nat Commun, 2018 9(1):28
- Nat Commun, 2018 9(1):5416
- Mol Cell, 2018 69(6):923-937
- J Exp Med, 2018 215(7):1913-1928
- Clin Cancer Res, 2018 10.1158/1078-0432.CCR-18-0693
- J Exp Clin Cancer Res, 2018 37(1):318
- Cancer Res, 2018
- Cancer Res, 2018 78(2):436-450
- Cancer Res, 2018 78(4):1017-1030
- J Control Release, 2018 277:48-56
- Cancer Immunol Res, 2018 10.1158/2326-6066
- Adv Healthc Mater, 2018 7(17):e1800533
- Cell Syst, 2018 7(2):161-179
- Cell Death Dis, 2018 9(3):325
- Cell Death Dis, 2018 9(2):29
- Cell Death Dis, 2018 9(6):679
- Cell Chem Biol, 2018 25(2):175-184
- Oncogene, 2018 37(31):4226-4238
- Oncogene, 2018 37(12):1576-1593
- Oncogene, 2018 37(24):3275-3289
- Oncogene, 2018
- Oncogene, 2018 37(7):944-952
- Oncoimmunology, 2018 7(8):e1450127
- Mol Cell Proteomics, 2018 17(10):1892-1908
- Eur J Med Chem, 2018 146:519-528
- Mol Oncol, 2018 12(6):869-882
- Mol Oncol, 2018 12(1):74-88
- Mol Oncol, 2018 12(2):224-238
- Life Sci, 2018 206:35-44
- Bioinformatics, 2018 34(17):i997-i1004
- Bioinformatics, 2018 34(23):4079-4086
- Mol Cancer Ther, 2018 17(10):2217-2225
- Mol Cancer Ther, 2018 17(7):1416-1429
- Mol Cancer Ther, 2018 17(4):806-813
- Mol Cancer Ther, 2018 17(1):84-95
- Int J Mol Sci, 2018 19(4)
- Oncotarget, 2018 9(18):14567-14579
- Oncotarget, 2018 9(23):16489-16500
- Oncotarget, 2018 9(47):28294-28308
- Mol Cancer Res, 2018 16(5):833-845
- Neoplasia, 2018 20(11):1121-1134
- Cell Signal, 2018 42:30-43
- Sci Rep, 2018 8(1):587
- Sci Rep, 2018 8(1):10724
- Pigment Cell Melanoma Res, 2018 31(2):253-266
- ACS Med Chem Lett, 2018 9(12):1199-1204
- Onco Targets Ther, 2018 11:8293-8299
- Biochimie, 2018 148:1-11
- Endocr Relat Cancer, 2018 25(1):99-109
- Endocr Relat Cancer, 2018 25(4):471-480
- BMC Cancer, 2018 18(1):675
- BMC Cancer, 2018 18(1):1219
- PLoS One, 2018 13(2):e0191696
- PLoS One, 2018 13(4):e0195956
- Biol Chem, 2018 399(7):649-659
- Biophys J, 2018 114(6):1499-1511
- Med Sci Monit, 2018 24:3002-3010
- Cancer Biomark, 2018
- BMC Syst Biol, 2018 12(1):33
- Melanoma Res, 2018 28(5):390-397
- Melanoma Res, 2018 28(6):521-526
- Melanoma Res, 2018
- Mol Biol (Mosk), 2018 52(3):466-473
- Small GTPases, 2018 10.1080/21541248.2018.1446697
- Nat Commun, 2017 8:15262
- Nat Commun, 2017 8(1):2249
- J Exp Med, 2017 214(6):1691-1710
- EMBO J, 2017 36(5):646-663
- EMBO J, 2017 36(5):604-616
- Cancer Res, 2017 77(7):1599-1610
- Proc Natl Acad Sci U S A, 2017 114(29):E5930-E5939
- Genes Dev, 2017 31(17):1809-1820
- Cancer Lett, 2017 402:100-109
- Cell Death Dis, 2017 8(2):e2594
- Cell Death Dis, 2017 8(8):e3029
- Oncogene, 2017 36(4):446-457
- JCI Insight, 2017 2(3):e89473
- Oncogene, 2017 36(27):3842-3851
- Elife, 2017 6. pii: e18970
- Blood Adv, 2017 30;1(24):2147-2160
- J Med Chem, 2017 60(1):180-201
- Oncoimmunology, 2017 7(2):e1392426
- Mol Cell Proteomics, 2017 16(4):663-679
- Antioxid Redox Signal, 2017 26(15):864-877
- Mol Oncol, 2017 11(12):1806-1825
- Int J Cancer, 2017 140(12):2758-2770
- Arch Toxicol, 2017 91(8):2921-2938
- Stem Cell Reports, 2017 8(5):1379-1391
- Cancer Cell Int, 2017 17:86
- J Clin Endocrinol Metab, 2017 102(8):2930-2940
- Mol Cancer Ther, 2017 16(5):936-947
- Mol Cancer Ther, 2017 16(10-:2130-2143
- Int J Mol Sci, 2017 18(10)
- Oncotarget, 2017 8(46):80393-80404
- Oncotarget, 2017 8(1):900-914
- Oncotarget, 2017 8(51):89182-89193
- Oncotarget, 2017 8(48):84210-84223
- Oncotarget, 2017 8(49):84743-84760
- Oncotarget, 2017 8(7):11460-11479
- Mol Cell Biol, 2017 37(18)e00061-17
- Mol Cancer Res, 2017 15(9):1265-1274
- Lab Invest, 2017 97(2):217-227
- J Biol Chem, 2017 292(28):11727-11739
- Front Oncol, 2017 7:95
- Sci Rep, 2017 7(1):16345
- Mol Carcinog, 2017 56(8):1965-1976
- Sci Rep, 2017 7:44206
- Sci Rep, 2017 7(1):11943
- Pigment Cell Melanoma Res, 2017 30(5):467-476
- Transl Lung Cancer Res, 2017 6(5):600-610
- Cancer Med, 2017 6(7):1652-1664
- J Cancer, 2017 8(15):2933-2943
- Biotechnol Bioeng, 2017 114(12):2868-2882
- BMC Cancer, 2017
- PLoS ONE, 2017
- PLoS One, 2017 12(1):e0170445
- PLoS One, 2017 12(8):e0183498
- J Cancer Res Clin Oncol, 2017 143(3):447-455
- Biochim Biophys Acta Gen Subj, 2017 1861(11 Pt B):2980-2992
- Tumour Biol, 2017 39(9):1010428317721620
- J Clin Invest, 2016 126(1):68-84
- Nat Chem Biol, 2016 12(7):531-8
- Hepatology, 2016 64(2):488-500
- Genome Biol, 2016 17:80
- Clin Cancer Res, 2016 22(1):230-242
- EMBO J, 2016 35(5):462-78
- Leukemia, 2016 30(4):937-46
- Cancer Res, 2016 76(9):2720-30
- Cancer Res, 2016 76(6):1476-84
- EMBO Mol Med, 2016 8(10):1143-1161
- Proc Natl Acad Sci U S A, 2016 113(34):E5005-13
- Br J Dermatol, 2016 175(6):1221-1231
- Cell Rep, 2016 15(1):171-180
- Cell Rep, 2016
- Oncogene, 2016 35(40):5295-5303
- Oncogene, 2016 35(17):2166-77
- EMBO Rep, 2016 17(5):724-38
- J Med Chem, 2016 59(3):925-33
- Cell Death Discov, 2016
- J Invest Dermatol, 2016 136(12):2475-2484
- Int J Cancer, 2016 138(9):2257-62
- J Clin Endocrinol Metab, 2016 101(3):962-71
- Mol Cancer Ther, 2016 15(6):1163-76
- Mol Cancer Ther, 2016 15(10):2442-2454
- Mol Cancer Ther, 2016 15(7):1460-71
- Oncotarget, 2016 8(35):58021-58036
- Oncotarget, 2016 7(21):30453-60
- Oncotarget, 2016 7(34):55128-55140
- Oncotarget, 2016 7(38):60858-60871
- Oncotarget, 2016 7(15):19948-59
- Oncotarget, 2016 7(4):3947-65
- Oncotarget, 2016 7(15):19997-20015
- Oncotarget, 2016 7(44):71211-71222
- Oncotarget, 2016 7(15):19575-88
- Oncotarget, 2016 7(43):70779-70793
- Oncotarget, 2016 7(14):17665-80
- Oncotarget, 2016 7(21):30907-23
- Oncotarget, 2016 7(46):75839-75853
- Am J Cancer Res, 2016 6(5):1040-52
- Mol Cancer Res, 2016 14(6):563-73
- Mol Cancer Res, 2016 14(10):1009-1018
- J Biol Chem, 2016 291(9):4323-33
- Sci Rep, 2016 6:26803
- Sci Rep, 2016 6:23713
- Sci Rep, 2016 6:27454
- Dis Model Mech, 2016 9(7):811-20
- Mol Cell Endocrinol, 2016 431:123-32
- Endocr Relat Cancer, 2016 23(3):135-46
- Methods Mol Biol, 2016 1407:229-50
- theses.fr, 2016
- Nat Struct Mol Biol, 2015 22(1):37-43
- Nat Commun, 2015 6:7103
- Nat Commun, 2015 6:6683
- Mol Cell, 2015 57(3):521-36
- Cancer Res, 2015 75(1):216-29
- Cancer Res, 2015 75(21):4573-81
- EMBO Mol Med, 2015 7(9):1104-18
- J Natl Cancer Inst, 2015 108(6):djv406
- Cancer Lett, 2015 10.1016/j.canlet.2015.02.041
- Cell Rep, 2015 10.1016/j.celrep.2015.04.049
- Oncogene, 2015 10.1038/onc.2015.97
- Elife, 2015 4
- J Transl Med, 2015 13:191
- J Transl Med, 2015 13(1):37
- J Med Chem, 2015 58(4):1818-31
- J Invest Dermatol, 2015 135(7):1863-1872
- Biochem Pharmacol, 2015 93(3):290-304
- Oncotarget, 2015 6(36):39028-35
- Oncotarget, 2015 6(19):16902-11
- Oncotarget, 2015 6(31):31792-804
- Oncotarget, 2015
- Oncotarget, 2015 6(18):16488-506
- Oncotarget, 2015 6(28):24823-41
- Oncotarget, 2015 6(38):40535-56
- Int J Oncol, 2015 47(1):81-90
- J Biol Chem, 2015 290(40):24267-77
- Cell Signal, 2015 27(10):1939-48
- J Immunother, 2015 38(1):12-23
- PLoS One, 2015 10(4):e0123410
- PLoS One, 2015 10(2):e0118210
- Proteomics, 2015 15(2-3):327-39
- Leuk Res, 2015 10.1016/j.leukres.2015.08.017
- Nat Commun, 2014 5:3901
- J Clin Invest, 2014 124(11):5074-84
- Autophagy, 2014 10(6):1120-36
- Cell Death Differ, 2014 21(12):1936-49
- Clin Cancer Res, 2014 20(13):3446-57
- Cancer Res, 2014 74(17):4845-52
- Cancer Res, 2014 74(4):1067-78
- Cancer Res, 2014 74(15):4122-32
- Br J Dermatol, 2014 10.1111/bjd.13300
- Cancer Lett, 2014 355(1):130-40
- Cell Death Dis, 2014 5:e1278
- Eur J Cancer, 2014 50(7):1310-20
- Oncogene, 2014 10.1038/onc.2014.21
- J Transl Med, 2014 12(1):247
- J Invest Dermatol, 2014 134(6):1686-92
- J Invest Dermatol, 2014 134(2):430-40
- Mol Cancer Ther, 2014 13(7):1894-906
- Mol Cancer Ther, 2014 13(2):353-63
- Mol Cancer Ther, 2014 10.1158/1535-7163.MCT-14-0452
- Target Oncol, 2014 10.1007/s11523-014-0318-9
- Oncotarget, 2014 5(9):2513-28
- Oncotarget, 2014 5(19):9444-59
- Oncotarget, 2014 5(24):12607-20
- Oncotarget, 2014 5(20):10127-39
- Oncotarget, 2014
- Oncotarget, 2014 5(21):10732-44
- Development, 2014 141(13):2611-20
- Cell Cycle, 2014
- Arch Biochem Biophys, 2014 563:125-35
- Pharm Res, 2014 31(12):3487-502
- Biomed Res Int, 2014 2014:568693
- Arch Dermatol Res, 2014 306(10):873-84
- J Pharm Pharm Sci, 2014 17(1):154-68
- J Surg Res, 2014 190(1):111-8
- Anticancer Res, 2014 34(9):4857-68
- Am J Clin Exp Immunol, 2014 3(1):43-56
- Rostock University, 2014 Lange F
- Nat Chem Biol, 2013 9(5):307-12
- Blood Cancer J, 2013 22;3(11):e163
- Clin Cancer Res, 2013 19(9):2584-91
- Clinical Cancer Research, 2013 19(9)
- Cell Death Dis, 2013 4:e914
- Elife, 2013 2:e00969
- J Transl Med, 2013 11:180
- Thyroid, 2013 24(3):453-62
- J Invest Dermatol, 2013 133(8):2041-9
- Oncogenesis, 2013 2:e44
- J Clin Endocrinol Metab, 2013 98(6):2502-12
- J Clin Endocrinol Metab, 2013 98(8):E1422-7
- Mol Cancer Ther, 2013 12(7):1171-9
- J Endocrinol Invest, 2013 36(11):1099-104
- Pigment Cell Melanoma Res, 2013 27(1):124-33
- Pigment Cell Melanoma Res, 2013 26(6):845-51
- Cancer Med, 2013 2(1):76-85
- Am J Med Sci, 2013 346(6):494-8
- J Biomol Screen, 2013 19(4):526-37
- Vet J, 2013 198(3):577-82
- Sci Transl Med, 2012 4(136):136ra70
- Proc Natl Acad Sci USA, 2012 109(31):E2127-33
- J Transl Med, 2012 10:15
- Oncoimmunology, 2012 1(9):1476-1483
- J Invest Dermatol, 2012 133(5):1269-77
- J Biol Chem, 2012 287(35):29887-98
- ACS Chem Biol, 2012 7(8):1429-35
- PLoS One, 2012 7(5):e36762
- PLoS One, 2012 7(12):e52760
- PLoS One, 2012 7(10):e47696
- J Invest Dermatol, 2011 131(10):2087-95
化学信息&溶解度
分子量 | 489.92 |
分子式 | C23H18ClF2N3O3S |
CAS号 | 918504-65-1 |
Smiles | CCCS(=O)(=O)NC1=C(C(=C(C=C1)F)C(=O)C2=CNC3=C2C=C(C=N3)C4=CC=C(C=C4)Cl)F |
储存条件(自收到货起) | 3年 -20°C(避光) 粉状 1年 -80°C(避光) 溶于溶剂 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 98 mg/mL ( 200.03 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 98 mg/mL ( 200.03 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 97 mg/mL ( 197.99 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 97 mg/mL ( 197.99 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 98 mg/mL ( 200.03 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
40%PEG300
5%TWEEN80
53%ddH2O
浓度:2mg/ml
(4.08mM)
操作示例:以 1 mL 工作液为例,取20 μL 100mg/ml的澄清DMSO储备液加到400 μL PEG300中,混合均匀使其澄清;向上述体系中加入50 μL Tween80,混合均匀使其澄清;然后继续加入530 μL ddH2O定容至1mL。工作液请现配现用!
|
|
5%DMSO
Corn oil
浓度:5mg/ml
(10.21mM)
操作示例:以 1 mL 工作液为例,取50μL100mg/ml的澄清DMSO储备液加到950μL玉米油中,混合均匀。工作液请现配现用!
|
|
4%DMSO
30%PEG300
5%Tween80
61%ddH2O
浓度:1.25mg/ml
(2.55mM)
操作示例:以 1 mL 工作液为例,取40μL31.25mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入610μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。